Centogene GmbH (CENTOGENE) and Amarey Nova Medical Group (Amarey) are pleased to announce a strategic exclusive partnership in Colombia, as of September 2015.
Amarey is well-established as a distributor of pharmaceuticals, medical equipment, and devices with more than 30 years’ experience in the Colombian market. Its CEO, Mr. Octavio Amaya, was the visionary who founded the company in 1984. In the past three decades Amarey has attained many successes in the healthcare sector of Colombia and has been able to exclusively represent leading brands such as Roche, Biotest, Chiesi, Intuitive, Nihon Kohden, and Stryker by building long lasting relationships.
It has always been Amarey’s aim to provide their customers with excellent services and processes, and to support top-quality products. As a result of their constant pursuit of excellence, they were recognized by the Colombian Government with the “2014 Colombian Award to Quality Management”, which portraits their commitment to patient safety by continuously serving the Colombian population and symbolizes their intention to be the best distributor.
Amarey is constantly seeking to provide excellent health solutions. In the field of genetic diagnostics they launched genomic testing in Colombia and other Latin American countries through their successful partnership with Genomic Health, which has led them to the top distributor award in Latin America in various years and place Colombia as the leading country in this type of patient analysis. The field of genetic diagnostics is growing, and Amarey is planning to play a major role in this development joining a new strategic alliance with CENTOGENE.
CENTOGENE is the worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio comprising more than 2,800 genes. CENTOGENE has revolutionized clinical interpretation with highest medical quality. Their strategic alliance with Amarey will enable both partners to bring the benefits of early and comprehensive diagnosis of hereditary diseases to the Colombian population and to bring patients closer to proper diagnosis and effective treatment.
It is of the upmost importance to Amarey and CENTOGENE to help Colombian patients have a better quality of life and be able to access the best technologies available worldwide. This motivation is something that is inherent in the organization of both companies and will continue to be supported by educational activities and will continue to be supported by educational activities to train both patients and medical groups towards the management of hereditary and rare diseases that are not as well-known.